drugset / Trial / NCT01774981
Study of LY3016859 in Participants With Diabetic Nephropathy
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this two-part study is to investigate the safety, tolerability and efficacy of LY3016859 after multiple intravenous (IV) dosing's in participants with diabetic nephropathy (DN). Part A will be dose escalation for safety and tolerability and Part B will evaluate Proteinuria.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fepixnebart | Monoclonal antibody | 10 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 250 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 750 mg | Intravenous |